Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
For some people with HIV treatment failure, personal difficulties with adherence may be at the root of the problem.
A review of randomized controlled trials found that the main apparent benefit of such testing occurred among those with virologic failure.
So argued researchers behind a study that switched people from triple-antiretroviral regimens to Tivicay monotherapy.
Tivicay (dolutegravir) is a next-generation integrase inhibitor.
So long as the viral load doesn’t hit 50 or above, there is likely no reason to switch antiretrovirals.
There is an apparent link between low vitamin D levels and a raised risk of both HIV disease progression and virologic failure among people wh...
Those who experience virologic failure when taking a first-line ritonavir-boosted protease inhibitor to treat HIV may be better off staying on...
There is a vast range in outcomes of success at suppressing HIV with antiretroviral treatment among people taking the drugs in poorer nations.
HIV-positive people on treatment who have a persistently detectable viral load, even a very low one, are at an increased risk for treatment fa...
A new study argues that consumption of alcohol appears unrelated to CD4 levels or treatment failure rates.
Computerized alerts to health care providers about their HIV patients improved patient outcomes in a study of one large clinic in Boston.
There is a 40 percent higher risk of virologic failure among blacks, compared with whites, who are starting HIV treatment for the first time,...
People who didn’t adhere to their antiretroviral (ARV) treatment regimen, or who started treatment with a high viral load, were more likely to...
Switching from Kaletra (lopinavir plus ritonavir) to Isentress (raltegravir) when viral load is undetectable might help reduce elevated choles...
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.